Itrol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itrol

Quick Facts

Property Description
Active ingredient Itraconazole (C35H38Cl2N8O4)
Form Capsule, Oral solution, Tablet
Pharmacological class Triazole Antifungal
Common use Systemic fungal infections
Origin Synthetic derivative

What Type of Medicine is Itrol and What Does It Contain?

Itrol is a synthetic, prescription-only anti-infective medication whose core function is to combat fungal organisms. Its single active ingredient is Itraconazole, a compound classified specifically as a triazole antifungal agent within the broader azole antifungal pharmacological class. This chemical identity as a triazole derivative establishes its capability as a potent agent intended for systemic use. Itrol is formulated for oral administration and is available as a capsule, a tablet, and an oral solution, providing flexibility for therapeutic use.


What is the General Purpose of Itrol?

The general therapeutic purpose of Itrol is to serve as a broad-spectrum anti-infective for addressing the presence and spread of pathogenic fungi. The medication functions by targeting the core structure of the fungal cell; it acts as a Fungal Ergosterol Synthesis Inhibitor, thereby preventing the creation of ergosterol, a vital building block necessary for fungal cell membrane integrity. This mechanism defines its general utility in managing systemic fungal infections and other persistent mycoses that require a potent, internally absorbed agent. Itraconazole is clinically recognized as a key agent in the management of deep-seated mycoses, offering a necessary treatment for internal fungal problems.


How Does Itrol Differ from Other Antifungals?

Itraconazole's primary distinction is its triazole structure, granting it a particularly broad-spectrum efficacy compared to some older antifungal classes. This property ensures it can address more complex or widespread fungal infections that require a deep-acting, systemic approach, rather than those addressable by simpler topical solutions. The broad scope of Itraconazole's use across various susceptible fungi establishes its importance in the pharmaceutical toolkit for infectious diseases. This therapeutic versatility and broad pharmacological applicability are major factors supporting its use in treating established or extensive fungal problems.

What side effects are possible with Itrol?

Possible side effects and safety information

The official safety profile for Itrol (Itraconazole) details adverse reactions organized by frequency and affected body system, based on regulatory classifications. These classifications are defined by government health authorities to communicate the medicine’s risk profile, focusing on factual, descriptive safety information.

Adverse effects are categorized by System-Organ Class (SOC), including Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.


Regulatory Classification of Common Reactions

Adverse reactions classified as Common (occurring in 1/100 to <1/10 patients) in regulatory documents typically include headache, nausea, vomiting, abdominal pain, and diarrhea. Elevated liver enzymes are also commonly reported. Uncommon reactions (1/1,000 to <1/100) include edema, hypertension, and menstrual disorders.


Serious Adverse Reactions and Restrictions

Regulatory documents explicitly highlight the potential for Serious Adverse Reactions, including Congestive Heart Failure (CHF) and Hepatotoxicity, which can progress to fatal hepatic failure. The use of Itrol is formally contraindicated in patients with evidence of ventricular dysfunction, except for the treatment of life-threatening fungal infections. The label also documents Peripheral Neuropathy, which may be persistent upon discontinuation of treatment, and severe skin reactions such as Stevens-Johnson syndrome.

Specific safety statements address certain groups: Caution is required for use in patients with Hepatic or Renal Impairment. Additionally, the risk of CHF is noted to increase with the total daily dose, and monitoring of hepatic function is a mandatory element of the official prescribing information.

Overdose and Emergency Response

The official regulatory profile for Itrol overdose emphasizes prompt action due to the potential for severe, life-threatening outcomes.

Overdose Manifestations and Systems Affected

  • Documented Presentations: Potential overdose may present with clinical signs consistent with Congestive Heart Failure (CHF), such as sudden weight gain, swelling, or shortness of breath, and signs of Hepatotoxicity, including jaundice or severe upper stomach pain. These represent the most serious documented risks. Severe toxicity also involves potential life-threatening cardiac dysrhythmias. Limited clinical information exists regarding the specific clinical signs of acute massive overdose.
  • Physiological Systems: The primary systems documented as affected by severe toxicity are the Cardiovascular system (risks include QT prolongation, severe dysrhythmias, and negative inotropy) and the Hepatic system (potential for liver failure).

Required Emergency Actions

Seek emergency medical attention immediately if an overdose is suspected. Urgent medical care is required when signs of serious toxicity, such as those consistent with CHF or Hepatotoxicity, develop, which also mandates the discontinuation of the drug.

  • Antidote Status: No specific antidote is known for Itrol overdose. Due to its high protein binding, the substance is not removed by hemodialysis.
  • Management: Management focuses on the initiation of general supportive measures and symptomatic treatment, as required by official regulatory guidance.

Therapeutic Uses of Itrol

Itrol (Itraconazole) is a triazole antifungal applied in situations involving certain distressing symptoms caused by established or high-risk fungal pathogens. Its therapeutic role is relevant across several domains, offering supportive symptomatic assistance for conditions marked by increased discomfort or tension.


Key Therapeutic Domains

The medication is commonly used to help manage conditions presenting with systemic or localized discomfort, such as Histoplasmosis and Blastomycosis, as well as in localized, persistent issues such as Onychomycosis (nail fungus) and extensive Dermatomycoses (skin infections). It also plays a role in managing potential infections by providing supportive relief in contexts involving heightened systemic burden in immunocompromised patients, and is relevant for easing challenging symptoms of Esophageal Candidiasis.

“Itrol is considered relevant for managing symptoms that may become more disruptive during flare-ups and when conditions involve chronic, extensive manifestations.”

This action supports the patient during difficult episodes by easing the overall symptom load and addressing the noticeable physiological strain associated with these conditions. For localized mycoses, this use supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Relief for Skin and Nail Symptoms

Condition Category Symptom Management Benefit
Keratinous Mycoses Helps address physical manifestations like nail thickening and skin rash, contributing to comfort.
Systemic Mycoses Supports the easing of overall symptom load and physiological strain associated with disseminated disease.
Candidiasis Applied to ease challenging symptoms, such as difficulty swallowing, helping maintain functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Itrol (Itraconazole) — Official Regulatory Information

This section provides the official eligibility and non-eligibility classifications for Itrol (Itraconazole), strictly as documented in governmental regulatory sources.


Eligibility Scope

Category Status as Stated in Label
Populations for whom use is allowed Adult patients (subject to no contraindications).
Populations for whom use is not recommended Pediatric population (safety and efficacy not established). Elderly patients (use with caution).
Populations for whom use is contraindicated Patients with known hypersensitivity to Itraconazole. Patients with evidence or history of Ventricular Dysfunction/Congestive Heart Failure (CHF) when treating onychomycosis. Patients taking certain prohibited CYP3A4 substrate medications.
Pregnancy and lactation eligibility status Pregnancy: Contraindicated for non-life-threatening indications. Lactation/Breastfeeding: Not recommended; benefits must be weighed against risks.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification
Eligibility severity classification Contraindicated; Conditional Use; Caution; Not Established.
Eligibility-context constraints The CHF contraindication is context-dependent, restricted specifically to the treatment of onychomycosis.

Connection to the overall eligibility profile

Regulatory documents define Itrol's eligibility by establishing absolute prohibitions based on cardiac status and co-medication risks. For serious infections, the drug is available under conditional use, where the potential benefit must clearly outweigh the risk. For populations with hepatic or renal impairment, or for pediatric use, eligibility is defined by a status of caution or use not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Itrol (Itraconazole) is defined by its role as a potent inhibitor of both Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). This pharmacokinetic constraint formally results in the increased plasma concentration of numerous co-administered medicinal products that are substrates for these enzyme and transporter systems. Such an increase creates a potential for serious, dose-related adverse effects and underpins the formal restrictions documented in the prescribing information.

Interaction Restrictions and Timing

Co-administration with numerous substances is officially prohibited (contraindicated) due to the inherent risk of life-threatening events resulting from high systemic exposure. Prohibited classes include certain Antiarrhythmics (e.g., Dofetilide, Quinidine), specific HMG CoA-Reductase Inhibitors (e.g., Lovastatin, Simvastatin), Ergot Alkaloids, and certain Psychotropics (e.g., Pimozide).

Constraint Category Official Regulatory Statement
Gastric Acidity Agents that reduce gastric acidity (e.g., antacids, H2 blockers) formally reduce the absorption of Itrol capsules. Antacids should be administered at least two hours after Itrol.
Food Requirement The maximal oral bioavailability of Itrol capsules is officially achieved when administered immediately after a full meal.
Population Note Contraindications exist for specific populations; for example, co-administration with Colchicine is prohibited in subjects with moderate to severe renal or hepatic impairment.

Mechanism of Action

Molecular Targeting of Fungal Membrane Synthesis

The mechanism of Itrol is focused on targeting the fungal enzyme Lanosterol 14alpha-demethylase, a specific type of Cytochrome P450 enzyme critical for the fungal ergosterol biosynthesis pathway. The drug acts as a selective inhibitor by complexing with the enzyme's haem iron, which directly halts the production of ergosterol, the key lipid required for the structural integrity and function of the fungal cell membrane.


Fungal Cellular Destruction Cascade

The drug initiates a cellular destruction cascade through two linked physiological effects: the absence of ergosterol weakens the cell membrane structure, and simultaneously, the drug causes the build-up of toxic 14-methylated sterol intermediates. These dysfunctional molecules functionally impair the membrane, causing it to become rigid and excessively permeable. This double disruption results in the leakage of essential cellular contents, leading to the growth inhibition and eventual death of the fungal organism (a fungistatic/fungicidal action).


Basis for Mechanistic Selectivity

The drug's activity profile reflects its mechanistic selectivity; the molecule exhibits a significantly higher affinity for the fungal P450 enzyme than for the analogous P450 enzymes found in the host's body. However, the mechanism is subject to limitations, primarily acquired fungal resistance caused by mutations in the target enzyme or the active expulsion of the drug by fungal efflux pumps, which limits the drug's concentration at the enzyme binding site.

Dosage and Administration Information

Administration Scope and Forms

Itrol (Itraconazole) is a triazole antifungal prescribed for oral administration only. It is supplied in multiple official forms, including capsules, tablets, and an oral solution. Proper use is specific to the formulation; the capsule and oral solution are not interchangeable at the same dose, and capsules must be swallowed whole.


Official Dosing Patterns

Regimens are structured based on the specific infection being addressed, requiring use over defined periods. For systemic fungal infections, a loading dose is often utilized—such as 200 mg administered three times daily for the initial three days. This is followed by a maintenance phase, typically 200 mg once or twice daily, which may continue for up to 12 months or longer. Conversely, treatments for certain localized infections may follow a cyclic pulse dosing schedule, requiring 200 mg twice daily for one week, followed by a drug-free interval.


Timing and Special Conditions

Administration timing relative to food is a critical factor for optimal absorption. Capsules and tablets must be taken immediately after a full meal. Conversely, the oral solution is required to be taken on an empty stomach (fasting). Total daily doses exceeding 200 mg (capsules) are generally administered as divided doses. For patients with renal or hepatic impairment, dose adjustment may be considered by a healthcare professional.

Recent Clinical Evidence

Acetaminophen: Recent Clinical Evidence

Recent clinical research on acetaminophen (APAP) focuses primarily on two areas: efficacy in specific patient populations and refining the understanding of its established hepatotoxicity risk.


Efficacy and Comparative Studies

Clinical trials continue to support acetaminophen's role in reducing fever and relieving mild to moderate pain. Comparative research suggests that in the treatment of acute pain, combinations of acetaminophen and ibuprofen may yield superior pain relief compared to certain opioid-containing formulations. Studies investigating its use for acute low back pain and osteoarthritis have generated mixed findings, indicating that its effectiveness may be limited for some chronic pain conditions.

Research has also explored new applications. For instance, a recent clinical trial in patients with sepsis and signs of organ dysfunction investigated intravenous acetaminophen, reporting that its administration was associated with a reduced risk of organ injury and acute respiratory distress syndrome (ARDS) compared to placebo.


Safety Profile and Risk Research

Hepatotoxicity (liver injury) remains the most critical adverse event associated with acetaminophen overdose, accounting for a majority of acute liver failure cases in many countries. Ongoing research is aimed at identifying specific genetic, nutritional, or co-morbid factors (such as chronic alcohol use) that may lower the threshold for toxicity in some individuals.

A significant area of recent focus is the association between prenatal acetaminophen exposure and neurodevelopmental outcomes in children. While some large observational studies have reported associations between frequent or prolonged use during pregnancy and increased rates of neurodevelopmental disorders, experts emphasize that these studies establish an association, not causation. Leading medical organizations currently maintain that acetaminophen remains a preferred non-opioid analgesic option for pain and fever during pregnancy, when used appropriately.

Frequently Asked Questions (FAQ)

Common questions about Itrol (FAQ)


Q: Is Itrol used to treat the underlying cause or just the symptoms?

Official information describes the drug’s role as targeting the underlying cause of infection. Its mechanism of action focuses on disrupting the fungal cell structure by inhibiting the production of a key component called ergosterol. This action is intended to lead to the breakdown of the fungal cell structure and subsequent growth inhibition or cell death, as described in official product information.


Q: What are the most common reasons why a doctor prescribes Itrol?

Regulatory bodies have approved Itrol for the treatment of various systemic fungal infections, which are infections that affect organs or spread through the body. This includes conditions such as blastomycosis, histoplasmosis, and aspergillosis. Itrol is also prescribed for fungal nail infections, known as onychomycosis.


Q: Are there any specific safety warnings for people over the age of 65 using Itrol?

Official regulatory guidance advises that Itrol should be used with caution in elderly patients. This is a general advisory statement found in the official safety materials.


Q: Can Itrol be taken by people with pre-existing liver conditions?

Official safety information requires caution to be exercised in patients with pre-existing hepatic (liver) impairment. Because Itrol is metabolized in the liver, dose adjustment may be considered by a prescribing healthcare professional, as outlined in the official prescribing information.


Q: Is Itrol safe to use during pregnancy according to official classifications?

Official regulatory documents indicate that the drug is formally contraindicated (prohibited) during pregnancy for non-life-threatening conditions. In cases of life-threatening fungal infections, use is conditional. Furthermore, the official label specifies that highly effective contraception be utilized during therapy and for a period of time after the last dose.


Q: Is Itrol safe to use while breastfeeding based on official guidance?

Breastfeeding is formally not recommended while a person is using Itrol. Official guidance suggests that the potential benefits of the drug must be weighed against the potential risks to the infant, as the medication may pass into breast milk.


Q: Can people with kidney problems use Itrol?

Caution is formally required for use in patients with pre-existing renal (kidney) impairment. Dose adjustment may be considered by a prescribing healthcare professional in this population, as noted in the official regulatory documents.


Q: What is the expected duration of treatment with Itrol for common conditions?

The duration of treatment is highly dependent on the type and severity of the infection being addressed. Official dosing patterns describe regimens ranging from short-term use, such as a cyclic pulse dosing schedule, to long-term maintenance phases that may continue for up to 12 months or longer for systemic infections.


Q: Is Itrol safe for children to use, according to regulatory bodies?

Regulatory bodies have determined that the safety and efficacy of Itrol have not been established in the pediatric population (children). Therefore, its use in this group is generally not covered by the standard regulatory approval.


Q: Are there any known interactions with herbal medicines while taking Itrol?

Itrol is a potent inhibitor of the CYP3A4 enzyme, a major metabolic pathway in the body. While official documents often focus on pharmaceutical drugs, this inhibition mechanism may affect many co-administered substances, including those found in certain herbal medicines.


Q: Do regulatory bodies list specific foods to avoid with Itrol?

Regulatory documents require Itrol capsules and tablets to be taken immediately after a full meal for maximal absorption. However, official information does not formally list specific dietary foods that must be avoided, focusing instead on the meal requirement.


Q: Is Itrol a long-term medicine or only for short-term use?

Official regulatory documents describe treatment regimens ranging from short-term use, such as a cyclic pulse dosing schedule, to long-term use in a maintenance phase for chronic or severe systemic infections. The duration of therapy depends on the condition being treated.


Q: Does taking Itrol require any changes to diet or activity?

Taking the capsules or tablets requires specific timing relative to a full meal, while the oral solution is taken on an empty stomach. Regulatory documents do not contain statements regarding required changes to general activity.


Q: Are there any specific vitamins or supplements known to interact with Itrol?

Itrol is a potent inhibitor of the CYP3A4 enzyme. This metabolic mechanism may increase the blood levels of various co-administered substances, including certain vitamins and supplements that are processed by this enzyme system.


Q: If I miss a dose of Itrol, what is the generally accepted advice?

Official patient information indicates the recommended procedure is to take the dose as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped entirely. Two doses should not be taken together.


Q: How does Itrol interact with common over-the-counter pain relievers?

Itrol is a potent inhibitor of the CYP3A4 enzyme. Potential interactions are dependent on whether the specific pain reliever is metabolized by the CYP3A4 enzyme. This inhibition mechanism may increase the levels of the pain reliever in the body.


Q: Is Itrol known to interact with alcoholic beverages?

Official documents and patient information specify that alcohol should be avoided while using this medication.


Q: Does Itrol affect blood sugar levels?

Postmarketing reports have noted cases suggestive of changes in blood sugar, including both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar), particularly in diabetic patients using Itrol.


Q: How do I know if the side effects I am experiencing are common for Itrol?

Adverse effects are formally classified by frequency in regulatory documents. These categories, such as 'Common' (occurring in 1/100 to less than 1/10 patients) or 'Uncommon,' are used to communicate the drug's risk profile in the official safety information.


Q: Are there any known interactions between Itrol and caffeine?

Itrol is a potent inhibitor of the CYP3A4 enzyme. The potential for interaction with substances like caffeine depends on whether the substance is metabolized by this enzyme system.


Q: Is Itrol known to cause changes in mood or sleep patterns?

The official safety profile organizes adverse reactions by System-Organ Class (SOC), which includes Nervous System Disorders. These categories may encompass observed changes in mood or sleep patterns.


Q: Why do official documents emphasize the use of Itrol only for specific conditions?

The drug's mechanism is specifically defined for targeting pathogenic fungi and managing systemic fungal infections. The FDA confirms the broad scope of Itrol's use across various susceptible fungi, establishing its therapeutic purpose.


Q: Can Itrol be cut in half or crushed?

Official regulatory documents explicitly state that Itrol capsules must be swallowed whole. Altering the capsule form is not part of the standard administration instructions.


Q: Is Itrol classified as a controlled substance?

Itrol is classified as a triazole antifungal agent. According to U.S. regulatory acts, it is not listed as a controlled substance.


Q: Are there specific times of day that are better for taking Itrol?

Administration timing is critical relative to food; capsules/tablets must be taken with a full meal, while the oral solution is taken on an empty stomach. There is no regulatory requirement specifying a better time of day (e.g., morning versus evening).


Q: What should be done if a potential drug interaction with Itrol is noted?

The official prescribing information documents formal restrictions and contraindications that prohibit co-administration with many substances. This is due to the inherent risk of serious, dose-related adverse effects resulting from the drug's action as a potent enzyme inhibitor.


Q: Is it normal for the effects of Itrol to change over time?

Official documents note that the drug's mechanism is subject to limitations, primarily the potential for acquired fungal resistance over time. This can be caused by mutations in the fungal organism or active expulsion of the drug, which may limit the intended therapeutic effect.


Q: Does Itrol require a prescription in most countries?

Itrol is classified in official documents as a prescription-only anti-infective medication.


Q: Can Itrol affect the results of certain laboratory tests?

Monitoring of hepatic function (liver function) is a mandatory element of the official prescribing information, which requires blood laboratory tests. This indicates the drug has known effects on results relating to liver health.


Q: Is there a maximum daily limit for Itrol?

The regulatory documents define regimens with a maximum loading dose administered three times daily. Additionally, official instructions advise that total daily doses exceeding a specific amount (200 mg) for capsules are generally administered as divided doses.


Q: What is the recommended approach if I am feeling unwell while on Itrol?

The official label highlights the potential for Serious Adverse Reactions, such as worsening Congestive Heart Failure (CHF) and severe Hepatotoxicity. These conditions are flagged as potential points of medical concern in the safety information.


Q: Does Itrol interact with common anesthetics for surgery?

Itrol is a potent inhibitor of the CYP3A4 enzyme. This mechanism may increase the blood levels of certain anesthetic agents used in surgery, which could potentially lead to an increased risk of serious side effects.


Q: What is the legal status of Itrol in terms of over-the-counter access?

Itrol is classified as a prescription-only medication. It is not available for purchase over the counter.


Q: Are there different formulations or strengths of Itrol available?

Itrol is supplied in multiple forms for oral administration, including capsules, tablets, and an oral solution. It is commonly supplied as a 100 mg per unit dose strength.


Q: What happens if Itrol is used by someone who is ineligible to take it?

Use is contraindicated (prohibited) in ineligible populations, such as those with existing heart conditions for certain uses. This is due to the inherent risk of life-threatening events resulting from high systemic exposure or the potential exacerbation of pre-existing conditions.


Q: How is Itrol eliminated from the body?

According to official pharmacokinetics data, the drug is extensively metabolized in the liver via the CYP3A4 enzyme pathway. It is then eliminated from the body via excretion in both the urine and feces.

How should Itrol be stored and disposed of?

Itraconazole must be stored according to specific, regulated requirements to ensure product stability.

Storage Requirements

Item Capsules Oral Solution
Temperature Controlled room temperature (15 C to 25 C). At or below 25 C.
Container Rule Keep in the original, tightly closed container.
Handling/Protection Must be protected from light and moisture; avoid excess heat. Must be protected from heat, light, and moisture; Do not freeze.
Child Safety Keep out of the reach of children.

Disposal Instructions

Expired or unused Itrol should be thrown away according to official regulatory guidelines. Disposal must be carried out by consulting a healthcare professional or by utilizing an approved community drug take-back program. If take-back options are unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed bag before being disposed of in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Itrol found in:

A-Z Index: